On the rebound of oil prices, U.S. stocks inclined. Dow component Pfizer Inc. declared a $16 billion deal.
Major News: Health-care stocks rallied 1.3% after Pfizer Inc. (NYSE:PFE), settled to buy Hospira Inc. (NYSE:HSP), which makes injectable drugs and infusion technologies. Hospira shareholders will get $90 a share in cash in cash for a total enterprise value of about $17 billion, in lieu of a premium of 39% to Wednesday’s closing price.
Shares of Pfizer inclined 2.60% and those of Hospira Inc. (NYSE:HSP) surged 35%. Both stocks are among the most active stocks of Healthcare sector.
The details about other active stocks among healthcare sector, in an afternoon trade includes:
Shares of Boston Scientific Corporation, (NYSE:BSX), inclined nearly 1.64% and closed at $ 15.21 in Thursday’s afternoon activity moving within a 52-week trading range of $11.10 - $15.28, following the news that Boston Scientific, generated sales of $1.887 billion during the fourth quarter ended December 31, 2014, contrast to the company’s guidance range for the quarter of $1.875 to $1.925 billion. This represents 7 percent operational proceed growth (constant currency basis, not including divested businesses) and 3 percent proceed growth on a stated basis, all contrast to the preceding year period. The company achieved adjusted earnings per share of $0.22 for the period, contrast to $0.21 a year ago, which represents 5 percent growth, and GAAP earnings declined 19 percent to $0.06 per share, contrast to $0.08 a year ago.*
Boston Scientific Corporation, (NYSE:BSX), develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Administration, and MedSurg.
Shares of the Opko Health, Inc. (NYSE:OPK), enhanced 3.45, after a multinational biopharmaceutical and diagnostics company, declared the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to conduct a Phase 2a study of OPKO’s long-acting version of coagulation Factor VIIa (Factor VIIa-CTP) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX.
Opko Health, Inc. (NYSE:OPK), is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. For more information, visit http://www.opko.com.
